W, S., CP, S., W, E., C, S., M, K., MHU, S., . . . M, R. (2017). 65Plus: Open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer. Dove Medical Press.
Cita Chicago Style (17a ed.)W, Schuette, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, y Reck M. 65Plus: Open-label Study of Bevacizumab in Combination with Pemetrexed or Pemetrexed/carboplatin as First-line Treatment of Patients with Advanced or Recurrent Nonsquamous Non-small-cell Lung Cancer. Dove Medical Press, 2017.
Cita MLA (8a ed.)W, Schuette, et al. 65Plus: Open-label Study of Bevacizumab in Combination with Pemetrexed or Pemetrexed/carboplatin as First-line Treatment of Patients with Advanced or Recurrent Nonsquamous Non-small-cell Lung Cancer. Dove Medical Press, 2017.